荣昌生物股票讨论区

Despite RemeGen's subdued revenue growth projections, it trades at a P/S ratio similar to the industry, suggesting investors may be less bearish than analysts. However, its weaker revenue outlook could risk a share price decline and pose a risk to shareholders.